Table 1.

Baseline patient characteristics.

Characteristics Nivolumab Cabiralizumab APX005M	Cohort 1 (n = 3) — 4 mg/kg 0.03 mg/kg	Cohort 2 (n = 6) 240 mg 4 mg/kg 0.03 mg/kg	Cohort 3 (n = 3) — 4 mg/kg 0.1 mg/kg	Cohort 4 (n = 5) 240 mg 4 mg/kg 0.1 mg/kg	Cohort 5 (n = 3) — 4 mg/kg 0.3 mg/kg	Cohort 6 (n = 6) 240 mg 4 mg/kg 0.3 mg/kg	Total (n = 26)
Age
Median	61	58	69	58	61	61	61
Range	59–66	40–71	69–73	40–63	60–67	44–84	40–84
Sex
Male (%)	3 (100)	4 (67)	1 (33)	5 (100)	3 (100)	4 (67)	20 (77)
Female (%)	0 (0)	2 (33)	2 (67)	0 (0)	0 (0)	2 (33)	6 (23)
Cancer type
Melanoma (%)	0 (0)	2 (33)	2 (67)	3 (60)	0 (0)	5 (83)	12 (46)
RCC (%)	3 (100)	4 (67)	1 (33)	2 (40)	2 (67)	1 (17)	13 (50)
NSCLC (%)	0 (0)	0 (0)	0 (0)	0 (0)	1 (33)	0 (0)	1 (4)
ECOG PS
0	3 (100)	4 (67)	2 (67)	5 (100)	1 (33)	4 (67)	19 (73)
1	0 (0)	2 (33)	1 (33)	0 (0)	2 (67)	2 (33)	7 (27)
All lines of prior treatment
Median	5	3	1	3	3	2	3
Range	3–5	1–5	1–5	1–6	1–6	1–4	1–6
Lines of prior immunotherapy-based treatment only
Median	4	2	1	3	3	2	2
Range	2–5	1–3	1–3	1–5	1–3	1–4	1–5
Response to prior immune checkpoint inhibitor(s)
Clinical benefit	3 (100)	1 (17)	2 (67)	3 (60)	2 (67)	4 (67)	15 (58)
1° resistance	0 (0)	5 (83)	1 (33)	2 (40)	1 (33)	2 (33)	11 (42)

Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance status.